© 2024
NPR for Northern Colorado
Play Live Radio
Next Up:
0:00
0:00
0:00 0:00
Available On Air Stations

Wal-Mart Food Push Echoes Earlier Move On Generic Drugs

First lady Michelle Obama and Bill Simon, president and CEO of Wal-Mart's U.S. unit, at a media briefing on the company's food initiative held in Washington, D.C.
Mark Wilson
/
Getty Images
First lady Michelle Obama and Bill Simon, president and CEO of Wal-Mart's U.S. unit, at a media briefing on the company's food initiative held in Washington, D.C.

Wal-Mart is making a big splash with a plan to sell less unhealthy food.

The bargain retailer, in case you didn't know, is the biggest grocer in the country. And on Thursday morning in Washington, Wal-Mart, with an assist from first lady Michelle Obama, said it will press suppliers to improve packaged foods by reducing sodium by 25 percent, cutting added sugar by 10 percent and virtually eliminating trans fats.

The changes are supposed to happen by 2015. Food watchdog Michael Jacobson, head of the , even got quoted praising Wal-Mart's moves in the company's release release.

Wal-Mart also said it would make healthier foods, such as fresh fruits and veggies, more affordable. And by opening more stores in cities, the company expects to make better food more widely available.

Now this isn't the first time the retailer has jumped on a consumer health issue in a big way. In late 2006, Wal-Mart started making a slew of generic prescription drugs available for $4 a month. And later, 90-day mail order prescriptions were added. Their price: $10.

There was some skepticism at the time. But Wal-Mart's move to offer generic drugs at such cheap prices prompted other retailers, including Target, to bring down their prices, too.

Wal-Mart figures that as of last fall, the cut-price generics it sells have saved consumers more than $3.4 billion.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

Scott Hensley edits stories about health, biomedical research and pharmaceuticals for NPR's Science desk. During the COVID-19 pandemic, he has led the desk's reporting on the development of vaccines against the coronavirus.